| __timestamp | BioCryst Pharmaceuticals, Inc. | Corcept Therapeutics Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 34916000 |
| Thursday, January 1, 2015 | 13047000 | 36949000 |
| Friday, January 1, 2016 | 11253000 | 45240000 |
| Sunday, January 1, 2017 | 13933000 | 62416000 |
| Monday, January 1, 2018 | 29514000 | 81289000 |
| Tuesday, January 1, 2019 | 37121000 | 100359000 |
| Wednesday, January 1, 2020 | 67929000 | 105326000 |
| Friday, January 1, 2021 | 118818000 | 122356000 |
| Saturday, January 1, 2022 | 159371000 | 152848000 |
| Sunday, January 1, 2023 | 213894000 | 184259000 |
Unleashing insights
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Corcept Therapeutics Incorporated and BioCryst Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, both companies have shown significant growth in their SG&A expenses, reflecting their expanding operations and market presence.
BioCryst Pharmaceuticals started with a modest SG&A expense of approximately $7.5 million in 2014, which surged by nearly 2800% to over $213 million by 2023. Meanwhile, Corcept Therapeutics saw its expenses grow from around $35 million to $184 million, marking a 426% increase. This trend highlights the aggressive expansion strategies employed by both companies.
Understanding these financial dynamics provides valuable insights into how these biotech firms allocate resources to support their growth and innovation strategies.
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Incyte Corporation and Corcept Therapeutics Incorporated
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
Corcept Therapeutics Incorporated and Perrigo Company plc: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs MorphoSys AG Trends and Insights
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
Research and Development Investment: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared